Sugi Predict

Sugi Predict / Compounds / SCHEMBL2089094

SCHEMBL2089094

SCHEMBL2089094

COc1ccc(C2(O)O[C@H](COCc3ccccc3)[C@@H](OCc3ccccc3)[C@H](OCc3ccccc3)[C@H]2OCc2ccccc2)cc1C1OCCO1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTPN1 P18031 6/20 0.35
▸ GJB2 P29033 2/20 0.34
▸ NT5E P21589 1/20 0.34
▸ PTPN2 P17706 1/20 0.34
▸ PTPN11 Q06124 1/20 0.34
▸ CDC25B P30305 4/20 0.33
▸ TACR2 P21452 1/20 0.33
▸ SSTR1 P30872 1/20 0.33
▸ SSTR2 P30874 1/20 0.33
▸ SSTR4 P31391 1/20 0.33
▸ SSTR3 P32745 1/20 0.33
▸ SSTR5 P35346 1/20 0.33
▸ SELL P14151 2/20 0.32
▸ SELP P16109 2/20 0.32
▸ HTR1A P08908 1/20 0.32
▸ BCHE P06276 1/20 0.32
▸ ACHE P22303 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18511211 1.00 PTPN1 (0.35) PTPN1GJB2NT5EPTPN2PTPN11
SCHEMBL14617864 0.93 GJB2 (0.33) PTPN1GJB2NT5EPTPN2PTPN11
SCHEMBL18521910 0.93 GJB2 (0.33) PTPN1GJB2NT5EPTPN2PTPN11
SCHEMBL16727619 0.93 GJB2 (0.33) PTPN1GJB2NT5EPTPN2PTPN11
SCHEMBL10177100 0.93 GJB2 (0.33) PTPN1GJB2NT5EPTPN2PTPN11
SCHEMBL10328080 0.93 GJB2 (0.33) PTPN1GJB2NT5EPTPN2PTPN11
SCHEMBL2087673 0.83 ERN1 (0.39) PTPN1NT5EPTPN2PTPN11CDC25B
SCHEMBL12407930 0.83 BCHE (0.34) PTPN1GJB2NT5EPTPN2PTPN11
SCHEMBL10226677 0.81 SELL (0.31) SELLSELP
SCHEMBL16730250 0.81 SELL (0.31) SELLSELP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49080-E1 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2022-05-24 — — US disclosed
US-9895389-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2018-02-20 — — US disclosed
US-20170042925-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2017-02-16 — — US disclosed
US-20150141354-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2015-05-21 — — US disclosed
US-20140274921-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2014-09-18 — — US disclosed
US-8828951-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2014-09-09 — — US disclosed
US-8466114-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2013-06-18 — — US disclosed
US-20130017993-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2013-01-17 — — US disclosed
US-20120178680-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2012-07-12 — — US disclosed
US-8163704-B2 Glycoside derivatives and uses thereof NOVARTIS AG (CH) 2012-04-24 — — US disclosed
US-20110171159-A1 Glycoside Derivatives and Uses Thereof NOVARTIS AG (CH) 2011-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170042925-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PTPN1 723/4885GJB2 2634/4885NT5E 1435/4885
US-20120178680-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PTPN1 723/4885GJB2 2634/4885NT5E 1435/4885
US-20150141354-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PTPN1 723/4885GJB2 2634/4885NT5E 1435/4885
US-20130017993-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PTPN1 723/4885GJB2 2634/4885NT5E 1435/4885
US-20110171159-A1 Glycoside Derivatives and Uses Thereof SLC5A1, SLC5A2, SLC2A1 PTPN1 723/4885GJB2 2634/4885NT5E 1435/4885
US-20140274921-A1 GLYCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, SLC5A2, SLC2A1 PTPN1 723/4885GJB2 2634/4885NT5E 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.